Locally Advanced Pancreatic Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Pancreatic adenocarcinoma is a highly aggressive form of cancer that originates from the cells lining the pancreatic ducts. Most cases of pancreatic cancer are classified as adenocarcinomas. At the time of diagnosis, the distribution of pancreatic cancer patients is approximately as follows: 20% with resectable tumors, 30% with locally advanced tumors, and 50% with metastatic disease. Locally advanced pancreatic cancer (LAPC) refers to a subgroup of patients who have pancreatic tumors that are deemed unresectable but have not yet spread to distant sites. These tumors exhibit certain characteristics that make them unsuitable for surgical removal, such as encasement of the superior mesenteric artery or coeliac axis of more than 180 degrees, unreconstructable superior mesenteric vein/portal vein occlusion, aortic involvement, or nodal involvement beyond the field of resection. The prognosis for LAPC patients falls between that of resectable and metastatic patients, with a median overall survival ranging from 5 to 11 months. The exact causes of the genetic and molecular changes leading to pancreatic cancer are not fully understood. However, certain risk factors have been identified that can increase the likelihood of developing the disease. These risk factors include smoking, inherited gene mutations (such as BRCA2 and PALB2 mutations), chronic pancreatitis, obesity, diabetes, and a family history of pancreatic cancer. In the treatment of stage III tumors, palliative FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) is currently considered the gold standard. Surgical resection remains the only treatment option with the potential for long-term survival and cure in pancreatic cancer. However, surgical intervention is often limited to a small percentage of patients due to the advanced stage at which pancreatic cancer is typically diagnosed.
Thelansis’s “Locally Advanced
Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Locally
Advanced Pancreatic Cancer treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Locally Advanced Pancreatic Cancer across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Locally Advanced Pancreatic Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment